Diversify Wealth Management LLC Buys 750 Shares of Catalent, Inc. (NYSE:CTLT)

Diversify Wealth Management LLC boosted its stake in Catalent, Inc. (NYSE:CTLT) by 9.2% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 8,921 shares of the company’s stock after buying an additional 750 shares during the period. Diversify Wealth Management LLC’s holdings in Catalent were worth $530,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Nisa Investment Advisors LLC raised its position in shares of Catalent by 1.7% in the second quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock valued at $619,000 after buying an additional 185 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after buying an additional 212 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in shares of Catalent by 1.1% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company’s stock valued at $1,179,000 after acquiring an additional 220 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Catalent by 3.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company’s stock valued at $432,000 after acquiring an additional 278 shares in the last quarter. Finally, Longfellow Investment Management Co. LLC boosted its holdings in Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after acquiring an additional 305 shares during the last quarter.

Insider Transactions at Catalent

In other news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares in the company, valued at $2,177,150.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.31% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on CTLT shares. StockNews.com began coverage on shares of Catalent in a research report on Saturday, October 12th. They issued a “hold” rating on the stock. William Blair restated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 price target on shares of Catalent in a report on Thursday, July 11th. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Finally, Robert W. Baird restated a “neutral” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. Nine equities research analysts have rated the stock with a hold rating, According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $59.83.

Catalent Price Performance

Shares of NYSE CTLT opened at $58.60 on Friday. The firm has a market capitalization of $10.61 billion, a P/E ratio of -9.65, a P/E/G ratio of 2.14 and a beta of 1.15. The firm’s 50-day moving average price is $60.08 and its 200-day moving average price is $57.93. The company has a current ratio of 2.52, a quick ratio of 1.96 and a debt-to-equity ratio of 1.35. Catalent, Inc. has a 1-year low of $31.80 and a 1-year high of $61.20.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Thursday, August 29th. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.13. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The business had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.23 billion. Equities research analysts anticipate that Catalent, Inc. will post 0.95 earnings per share for the current fiscal year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.